ClinicalTrials.gov record
Completed Phase 3 Interventional Results available

Efficacy and Safety of Dalbavancin for the Treatment of Acute Bacterial Skin and Skin Structure Infections

ClinicalTrials.gov ID: NCT01431339

Public ClinicalTrials.gov record NCT01431339. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 19, 2026, 7:52 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 3, Randomized, Double-Blind, Double-Dummy Study to Compare the Efficacy and Safety of Dalbavancin to a Comparator Regimen (Vancomycin and Linezolid) for the Treatment of Acute Bacterial Skin and Skin Structure Infections

Study identification

NCT ID
NCT01431339
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
Durata Therapeutics Inc., an affiliate of Allergan plc
Industry
Enrollment
739 participants

Conditions and interventions

Interventions

  • IV Dalbavancin Drug
  • Vancomycin/Linezolid Drug

Drug

Eligibility (public fields only)

Age range
18 Years to 85 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jun 30, 2011
Primary completion
Oct 31, 2012
Completion
Nov 30, 2012
Last update posted
Feb 11, 2014

2011 – 2012

United States locations

U.S. sites
30
U.S. states
11
U.S. cities
29
Facility City State ZIP Site status
Durata Clinical Site Montgomery Alabama 36106
Durata Clinical Site Anaheim California 92804
Durata Clinical Site Buena Park California 90620
Durata Study Site Chula Vista California 91911
Durata Clinical Site Long Beach California 90813
Durata Study Site Los Angeles California 90015
Durata Study Site Norwalk California 90650
Durata Study Site Oxnard California 93030
Durata Study SIte San Diego California 92120
Durata Study Site Stockton California 95204
Durata Clinical Site Boyton Beach Florida 33435
Durata Clinical Site Fort Meyers Florida 33966
Durata Clinical Site Miami Florida 33015
Durata Study Site Orlando Florida 32837
Durata Clinical Site Saint Cloud Florida 34769
Durata Clinical Site Augusta Georgia 30901
Durata Study Site Columbus Georgia 31904
Durata Clinical Site Chicago Illinois 60637
Durata Study Site Baton Rouge Louisiana 70809
Durata Study Site New Orleans Louisiana 70112
Durata Study Site Shreveport Louisiana 71101
Durata Study Site Zachary Louisiana 70791
Durata Study Site Las Vegas Nevada 89109
Durata Study Site Springfield Ohio 45502
Durata Study Site Philadelphia Pennsylvania 19103
Durata Study Site Austin Texas 78701
Durata Clinical Site Austin Texas 78752
Durata Clinical Site Houston Texas 77055
Durata Study Site Richmond Texas 77469
Durata Study Site Middleton Wisconsin 53562

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 107 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT01431339, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Feb 11, 2014 · Synced May 19, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT01431339 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →